Haemonetics (HAE) Receivables (2010 - 2026)

Haemonetics has reported Receivables for 17 years, with the latest figure at $216.1 million in Q2 2026.

• On a quarterly basis, Receivables rose 7.63% year-over-year to $216.1 million in Q2 2026; TTM through Jun 2026 was $216.1 million, a 7.63% increase from a year earlier, with the FY2026 full-year figure at $216.9 million, up 7.01% from the prior year.
• Receivables was $216.1 million for Q2 2026 at Haemonetics, roughly flat from $216.9 million in the prior quarter.
• The five-year high for Receivables was $216.9 million in Q1 2026, with the low at $146.5 million in Q3 2022.
• Average Receivables over 5 years is $191.0 million, with a median of $200.8 million recorded in 2025.
• The sharpest annual moves came in 2022 and 2025: Receivables climbed 24.95% in 2022, then dropped 7.66% in 2025.
• Over 5 years, Receivables stood at $181.1 million in 2022, then advanced by 16.85% to $211.6 million in 2023, then gained by 0.16% to $211.9 million in 2024, then slipped by 7.66% to $195.7 million in 2025, then climbed by 10.41% to $216.1 million in 2026.
• The last three Receivables figures came in at $216.1 million (Q2 2026), $216.9 million (Q1 2026), and $195.7 million (Q4 2025), per Business Quant data.